Dr Reddy’s launches anti-migraine drug in US

Hyderabad: City-based Dr Reddy's Laboratories on Tuesday said its acute migraine treatment injection Zembrace SymTouch is now commercially available in the US market. "Promius Pharma LLC, a subsidiary of DRL announced that Zembrace SymTouch injection is now commercially available in the US," the pharma major said in a release.

The company received an approval from the US Food and Drug Administration (USFDA) for Zembrace SymTouch injection in January this year. The injection is available as a prefilled, ready to use, single dose disposable injector. The new injection ‘is a welcome addition to the toolkit for acute treatment of migraine.

This 3-mg, easy-to-use subcutaneous injection of sumatriptan may be desired by migraine patients who need a medication that can rapidly treat migraine attacks,” said Roger Cady, Associate Executive Chairman, National Headache Foundation in US. At the time of USFDA approval, the company had said that the new product will be marketed in the US by Promius Pharma.

"ZembraceSym Touch is the first branded product in the company's neurology portfolio," said Raghav Chari, Executive Vice President (Propriety Products Group), Dr Reddy’s. The new anti-migraine injection is specifically designed for patients who experience certain migraine episodes and for whom a pill may not be the right option, he added.